MedTrace Logo

Alanyl-glutamine Supplementation of Standard Treatment for C. Difficile Infection

NCT02053350 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2022-06-07

Study results available
· View outcomes & findings →

Summary

The aim of this study is to test the efficacy of alanyl-glutamine supplementation in the treatment of C. difficile infection. We hypothesize that alanyl-glutamine when given with standard antibiotic treatment for C. difficile infection will decrease diarrhea, mortality and recurrent disease.

Conditions

  • Clostridium Difficile Infection

Interventions

DRUG

Alanyl-glutamine

Alanyl-glutamine, 44g, taken by mouth daily for 10 days

Sponsors & Collaborators

  • University of Virginia

    lead OTHER

Principal Investigators

  • Cirle A. Warren, M.D. · University of Virginia

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-04-05
Completion
2017-04-05

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02053350 on ClinicalTrials.gov